| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Ziprasidone | Ziprasidone 6-Chloro OxyIndole | VE006431 | View CAS 56341-37-8 |
| Ziprasidone | Ziprasidone Deschloro Impurity | VE006608 | View |
| Ziprasidone | Ziprasidone Dichloro Impurity | VE008315 | View CAS 118307-04-3 |
| Ziprasidone | Ziprasidone EP Impurity A | VL248001 | View CAS 87691-87-0 |
| Ziprasidone | Ziprasidone EP Impurity A (HCl Salt) | VE006678 | View CAS 87691-88-1 |
| Ziprasidone | Ziprasidone EP Impurity B | VL248002 | View CAS 1159977-56-6 |
| Ziprasidone | Ziprasidone EP Impurity C | VL248008 | View CAS 1159977-64-6 |
| Ziprasidone | Ziprasidone EP Impurity D | VL248007 | View CAS 1303996-68-0 |
| Ziprasidone | Ziprasidone EP Impurity E | VL248003 | View CAS 1159977-04-4 |
| Ziprasidone | Ziprasidone EP Impurity P | VL248009 | View CAS 223586-82-1 |
| Ziprasidone | Ziprasidone Impurity 1 | VE006625 | View CAS 118289-55-7 |
| Ziprasidone | Ziprasidone N-Oxide | VL248005 | View CAS 188797-76-4 |
| Ziprasidone | Ziprasidone Related Compound F | VE006449 | View |
| Ziprasidone | Ziprasidone S-Oxide | VL248006 | View CAS 188797-80-0 |
| Ziprasidone | Ziprasidone Sulfone Impurity | VE006252 | View CAS 188797-77-5 |
| Ziprasidone | Ziprasidone T-Butoxy Impurity | VL4200001 | View CAS 131779-46-9 |
| Ziprasidone | 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloro-1-(2-(6-chloro-2-oxoindolin-5-yl)ethyl)indolin-2-one | VE009930 | View |
| Ziprasidone | 6-Chloro-5-(2-chloro-1-hydroxyethyl)-1, 3-dihydro-2H-indol-2-one | VE0012076 | View CAS 884305-06-0 |
| Ziprasidone | 6-chloro-1-(2-(6-chloro-2-oxoindolin-5-yl)ethyl)-5-(2-chloroethyl)indolin-2-one | VE009934 | View |
Ziprasidone Related Compound
It can produce sleepiness because it antagonizes H1 receptors.
References
- Komossa, Katja, et al. “Ziprasidone versus Other Atypical Antipsychotics for Schizophrenia.” Cochrane Database of Systematic Reviews, Oct. 2009, https://doi.org/10.1002/14651858.cd006627.pub2. Accessed 28 Feb. 2023.
- Ionescu, Dawn F., et al. “Ziprasidone Augmentation for Anxious Depression.” International Clinical Psychopharmacology, vol. 31, no. 6, Nov. 2016, pp. 341–46, https://doi.org/10.1097/yic.0000000000000133. Accessed 28 Feb. 2023.
- “Ziprasidone (Geodon) | NAMI: National Alliance on Mental Illness.” Nami.org, 2023, www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Ziprasidone-(Geodon)#:~:text=Ziprasidone%20is%20a%20medication%20that,thinking%2C%20mood%2C%20and%20behavior. Accessed 28 Feb. 2023.
FAQ
Is ziprasidone a sedative?
Ziprasidone, unlike many other antipsychotics, has no appreciable affinity for mACh receptors and so has no anticholinergic adverse effects. Ziprasidone, like most other antipsychotics, is sedating owing to serotonin and dopamine blocking.
Can ziprasidone be used to treat anxiety?
Ziprasidone augmentation of escitalopram appears to be equally effective in the treatment of both anxious and nonanxious depression in terms of mood symptoms. The identified anxiolytic effect size for individuals with greater levels of anxiety, however, was not determined to be clinically significant.
Is ziprasidone a mood stabilizer?
Ziprasidone is a drug used to treat schizophrenia that operates in the brain. It’s sometimes referred to as a second-generation antipsychotic (SGA) or an atypical antipsychotic. Ziprasidone restores dopamine and serotonin balance to enhance cognition, mood, and behavior.
